Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.
Analysis of lymphoma treatment access reveals major disparities between academic and community settings, proposing practical solutions.
This Blood Reviews article comprehensively examines current LBCL treatment strategies in the post-CAR-T era and identifies major disparities in access to novel therapies between academic and community settings. The practical focus on real-world implementation of DLBCL management includes CAR-T patient selection, bispecific antibody sequencing, and community-feasible protocols relevant to the majority of US LBCL patients.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Rev
Why it surfaced
LBCL treatment landscape is rapidly evolving with CAR-T and bispecific antibodies; Blood Reviews is a peer-reviewed hematology journal; community-academic disparity framing provides practical clinical value; directly relevant to lymphoma watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.